Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations

Flanders, 2001, TGFβ, 719 Howe, 2003, Transforming growth factor β, 1119 Li, 2006, Transforming growth factor-beta regulation of immune responses, Annu Rev Immunol, 24, 99, 10.1146/annurev.immunol.24.021605.090737 Hyytiainen, 2004, Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation, Crit Rev Clin Lab Sci, 4, 233, 10.1080/10408360490460933 Fox, 2005, Current insights into the role of transforming growth factor-beta in bone resorption, Mol Cell Endocrinol, 243, 19, 10.1016/j.mce.2005.09.008 Rubtsov, 2007, TGFbeta signalling in control of T-cell-mediated self-reactivity, Nat Rev Immunol, 7, 443, 10.1038/nri2095 Kallapur, 1998, Phenotypes of TGFbeta knockout mice, 335 Kulkarni, 1998, The transforming growth factor beta-1 mouse: the phenotype and its implications for TGFbeta1 function, 369 Wahl, 2007, Transforming growth factor-beta: innately bipolar, Curr Opin Immunol, 19, 55, 10.1016/j.coi.2006.11.008 Weaver, 2007, IL-17 family cytokines and the expanding diversity of effector T cell lineages, Annu Rev Immunol, 25, 821, 10.1146/annurev.immunol.25.022106.141557 Godar, 1999, M6P/IGFII–receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-beta1, Eur J Immunol, 29, 1004, 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q Munger, 1999, The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis, Cell, 96, 319, 10.1016/S0092-8674(00)80545-0 Schultz-Cherry, 1994, Thrombospondin binds and activates the small and large forms of latent transforming growth factor-beta in a chemically defined system, J Biol Chem, 269, 26775, 10.1016/S0021-9258(18)47086-X Ribeiro, 1999, The activation sequence of thrombospondin-1 interacts with the latency-associated peptide to regulate activation of latent transforming growth factor-beta, J Biol Chem, 274, 13586, 10.1074/jbc.274.19.13586 Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev, 14, 163, 10.1101/gad.14.2.163 Yu, 2004, Transforming growth factor-beta facilitates breast carcinoma metastasis by promoting tumor cell survival, Clin Exp Metastasis, 2, 235, 10.1023/B:CLIN.0000037705.25256.d3 Todorovic, 2005, Latent TGF-beta binding proteins, Int J Biochem Cell Biol, 37, 38, 10.1016/j.biocel.2004.03.011 Abdalla, 2006, Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease, J Med Genet, 43, 97, 10.1136/jmg.2005.030833 Lebrin, 2004, Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction, EMBO J, 23, 4018, 10.1038/sj.emboj.7600386 Staton, 2007, Neuropilins in physiological and pathological angiogenesis, J Pathol, 212, 237, 10.1002/path.2182 Tordjman, 2002, A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response, Nat Immunol, 3, 477, 10.1038/ni789 Bruder, 2004, Neuropilin-1: a surface marker of regulatory T cells, Eur J Immunol, 34, 623, 10.1002/eji.200324799 O'Connor-McCourt, 1987, Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin, J Biol Chem, 262, 14090, 10.1016/S0021-9258(18)47909-4 Prud'homme, 2000, The inhibitory effects of transforming growth factor-beta-1 (TGF-beta1) in autoimmune diseases, J Autoimmun, 14, 23, 10.1006/jaut.1999.0339 Fainaru, 2007, TGFbeta-dependent gene expression profile during maturation of dendritic cells, Genes Immun, 8, 239, 10.1038/sj.gene.6364380 Wahl, 1987, Transforming growth factor type beta induces monocyte chemotaxis and growth factor production, Proc Natl Acad Sci USA, 84, 5788, 10.1073/pnas.84.16.5788 Reibman, 1991, Transforming growth factor beta 1, a potent chemoattractant for human neutrophils, bypasses classic signal-transduction pathways, Proc Natl Acad Sci USA, 88, 6805, 10.1073/pnas.88.15.6805 Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753 Yoshimura, 2006, Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells vs suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism, J Immunol, 177, 5377, 10.4049/jimmunol.177.8.5377 Laurence, 2007, Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation, Immunity, 26, 371, 10.1016/j.immuni.2007.02.009 Nakae, 2007, Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17, J Leukoc Biol, 81, 1258, 10.1189/jlb.1006610 Xu, 2007, Cutting edge: regulatory T cells induce CD4+CD25−Foxp3− T cells or are self-induced to become Th17 Cells in the absence of exogenous TGF-beta, J Immunol, 178, 6725, 10.4049/jimmunol.178.11.6725 Lebman, 1999, The role of TGF-beta in growth, differentiation, and maturation of B lymphocytes, Microbes Infect, 1, 1297, 10.1016/S1286-4579(99)00254-3 Borsutzky, 2004, TGF-beta receptor signaling is critical for mucosal IgA responses, J Immunol, 173, 3305, 10.4049/jimmunol.173.5.3305 Shull, 1992, Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease, Nature, 359, 693, 10.1038/359693a0 Geiser, 1993, Transforming growth factor beta 1 (TGF-beta 1) controls expression of major histocompatibility genes in the postnatal mouse: aberrant histocompatibility antigen expression in the pathogenesis of the TGF-beta 1 null mouse phenotype, Proc Natl Acad Sci USA, 90, 9944, 10.1073/pnas.90.21.9944 Letterio, 1998, Regulation of immune responses by TGF-beta, Annu Rev Immunol, 16, 137, 10.1146/annurev.immunol.16.1.137 Li, 2006, Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms, Immunity, 25, 455, 10.1016/j.immuni.2006.07.011 Li, 2007, T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation, Immunity, 26, 579, 10.1016/j.immuni.2007.03.014 Wahl, 2006, TGF-beta: a mobile purveyor of immune privilege, Immunol Rev, 213, 213, 10.1111/j.1600-065X.2006.00437.x Levings, 2006, Functional dynamics of naturally occurring regulatory T cells in health and autoimmunity, Adv Immunol, 92, 119, 10.1016/S0065-2776(06)92003-3 Zheng, 2007, IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells, J Immunol, 178, 2018, 10.4049/jimmunol.178.4.2018 Marie, 2005, TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells, J Exp Med, 201, 1061, 10.1084/jem.20042276 Pyzik, 2007, TGF-beta-1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets, J Leukoc Biol, 82, 335, 10.1189/jlb.1006644 Selvaraj, 2007, A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-beta, J Immunol, 178, 7667, 10.4049/jimmunol.178.12.7667 Oida, 2006, TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling, J Immunol, 177, 2331, 10.4049/jimmunol.177.4.2331 Fahlen, 2005, T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells, J Exp Med, 201, 737, 10.1084/jem.20040685 Faria, 2006, Oral tolerance: therapeutic implications for autoimmune diseases, Clin Dev Immunol, 13, 143, 10.1080/17402520600876804 Faria, 2005, Oral tolerance, Immunol Rev, 206, 232, 10.1111/j.0105-2896.2005.00280.x Roncarolo, 2006, Interleukin-10-secreting type 1 regulatory T cells in rodents and humans, Immunol Rev, 212, 28, 10.1111/j.0105-2896.2006.00420.x Werner, 2007, Keratinocyte–fibroblast interactions in wound healing, J Invest Dermatol, 127, 998, 10.1038/sj.jid.5700786 Frangogiannis, 2006, Targeting the inflammatory response in healing myocardial infarcts, Curr Med Chem, 13, 1877, 10.2174/092986706777585086 Ruiz-Ortega, 2007, TGF-beta signaling in vascular fibrosis, Cardiovasc Res, 74, 196, 10.1016/j.cardiores.2007.02.008 Leask, 2007, TGFbeta, cardiac fibroblasts, and the fibrotic response, Cardiovasc Res, 74, 207, 10.1016/j.cardiores.2006.07.012 Leask, 2006, Scar wars: is TGFbeta the phantom menace in scleroderma?, Arthritis Res Ther, 8, 213, 10.1186/ar1976 Cutroneo, 2007, Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression, Cell Physiol, 211, 585, 10.1002/jcp.20972 Gauldie, 2006, Smad3 signaling involved in pulmonary fibrosis and emphysema, Proc Am Thorac Soc, 3, 696, 10.1513/pats.200605-125SF Bottinger, 1997, Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor beta receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]-anthracene, Cancer Res, 57, 5564 Forrester, 2005, Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis, Cancer Res, 65, 2296, 10.1158/0008-5472.CAN-04-3272 Tian, 2004, Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines, Cancer Res, 64, 4523, 10.1158/0008-5472.CAN-04-0030 Wakefield, 2002, TGF-beta signaling: positive and negative effects on tumorigenesis, Curr Opin Genet Dev, 12, 22, 10.1016/S0959-437X(01)00259-3 Siegel, 2003, Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer, Nat Rev Cancer, 3, 807, 10.1038/nrc1208 Galliher, 2006, Role of transforming growth factor-beta in cancer progression, Future Oncol, 2, 743, 10.2217/14796694.2.6.743 Jakowlew, 2006, Transforming growth factor-beta in cancer and metastasis, Cancer Metastasis Rev, 25, 435, 10.1007/s10555-006-9006-2 Stover, 2007, A delicate balance: TGF-beta and the tumor microenvironment, J Cell Biochem, 101, 851, 10.1002/jcb.21149 Dong, 2007, The type III TGF-beta receptor suppresses breast cancer progression, J Clin Invest, 117, 206, 10.1172/JCI29293 Zavadil, 2005, TGF-beta and epithelial-to-mesenchymal transitions, Oncogene, 24, 5764, 10.1038/sj.onc.1208927 Han, 2005, Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis, J Clin Invest, 115, 1714, 10.1172/JCI24399 Muraoka, 2003, Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1, Mol Cell Biol, 23, 8691, 10.1128/MCB.23.23.8691-8703.2003 Oft, 1998, TGFbeta signaling is necessary for carcinoma cell invasiveness and metastasis, Curr Biol, 8, 1243, 10.1016/S0960-9822(07)00533-7 Biswas, 2007, Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression, J Clin Invest, 117, 1305, 10.1172/JCI30740 Arteaga, 1993, J Clin Invest, 92, 2569, 10.1172/JCI116871 Saunier, 2006, TGF beta inhibition for cancer therapy, Curr Cancer Drug Targets, 6, 565, 10.2174/156800906778742460 Pinkas, 2006, TGF-beta in cancer and as a therapeutic target, Biochem Pharmacol, 72, 523, 10.1016/j.bcp.2006.03.004 Ivanovic, 2006, Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients, Clin Chim Acta, 371, 191, 10.1016/j.cca.2006.02.027 Feltl, 2005, Post-treatment plasma transforming growth factor beta 1 (TGF-beta1) level predicts for late morbidity in patients with advanced head and neck cancer, Neoplasma, 52, 393 Fukuchi, 2004, Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer, Clin Cancer Res, 10, 2738, 10.1158/1078-0432.CCR-1096-03 Tsushima, 2001, Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer, Clin Cancer Res, 7, 1258 Sinnreich, 2004, Plasma levels of transforming growth factor-1beta and alpha2-macroglobulin before and after radical prostatectomy: association to clinicopathological parameters, Prostate, 61, 201, 10.1002/pros.20062 Gary Lee, 2002, Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivoin vitro, Am J Respir Crit Care Med, 165, 88, 10.1164/ajrccm.165.1.2104006 Benckert, 2003, Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells, Cancer Res, 63, 1083 Serafini, 2006, Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression, Semin Cancer Biol, 16, 53, 10.1016/j.semcancer.2005.07.005 Kobie, 2003, Transforming growth factor beta inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines, Cancer Res, 63, 1860 Chen, 2005, Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo, Proc Natl Acad Sci USA, 102, 419, 10.1073/pnas.0408197102 Kang, 2005, Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway, Proc Natl Acad Sci USA, 102, 13909, 10.1073/pnas.0506517102 Kang, 2003, A multigenic program mediating breast cancer metastasis to bone, Cancer Cell, 3, 537, 10.1016/S1535-6108(03)00132-6 Yin, 1999, TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development, J Clin Invest, 103, 197, 10.1172/JCI3523 Rose, 2006, Breast cancer-derived factors facilitate osteolytic bone metastasis, Bull Cancer, 93, 931 Guise, 2003, Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases, Clinical Orthopaedics and Related Research, 415, S32, 10.1097/01.blo.0000093055.96273.69 Bandyopadhyay, 2006, Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor, Cancer Res, 66, 6714, 10.1158/0008-5472.CAN-05-3565 Kakonen, 2002, Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways, J Biol Chem, 277, 24571, 10.1074/jbc.M202561200 Lahn, 2005, TGF-beta inhibitors for the treatment of cancer, Expert Opin Investig Drugs, 14, 629, 10.1517/13543784.14.6.629 Akhurst, 2006, Large- and small-molecule inhibitors of transforming growth factor-beta signaling, Curr Opin Investig Drugs, 7, 513 Tsuchida, 2006, Inhibitors of the TGF-beta superfamily and their clinical applications, Mini Rev Med Chem, 6, 1255, 10.2174/138955706778742759 de Gouville, 2006, Inhibition of ALK5 as a new approach to treat liver fibrotic diseases, Drug News Perspect, 19, 85, 10.1358/dnp.2006.19.2.977444 Liu, 2006, Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis, Liver Int, 26, 8, 10.1111/j.1478-3231.2005.01192.x Wick, 2006, Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma, Curr Pharm Des, 12, 341, 10.2174/138161206775201901 Breitkopf, 2005, Anti-TGF-beta strategies for the treatment of chronic liver disease, Alcohol Clin Exp Res, 29, 121S, 10.1097/01.alc.0000189284.98684.22 Burke, 2007, Fibrogenesis in Crohn's disease, Am J Gastroenterol, 102, 439, 10.1111/j.1572-0241.2006.01010.x Lim, 2006, Role of transforming growth factor-beta in the progression of heart failure, Cell Mol Life Sci, 63, 2584, 10.1007/s00018-006-6085-8 Cutroneo, 2007, for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression, J Cell Physiol, 211, 585, 10.1002/jcp.20972 Dabek, 2006, Transforming growth factor beta and cardiovascular diseases: the other facet of the ‘protective cytokine', Pharmacol Rep, 58, 799 Wojtowicz-Praga, 2003, Reversal of tumor-induced immunosuppression by TGF-beta inhibitors, Invest New Drugs, 2, 21, 10.1023/A:1022951824806 Ruzek, 2003, Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice, Immunopharmacol Immunotoxicol, 25, 235, 10.1081/IPH-120020473 Yang, 2002, Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects, J Clin Invest, 109, 1607, 10.1172/JCI200215333 Santiago, 2005, Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis, J Invest Dermatol, 125, 450, 10.1111/j.0022-202X.2005.23859.x Vilchis-Landeros, 2001, Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent, Biochem J, 355, 215, 10.1042/bj3550215 Bandyopadhyay, 2002, Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft, Cancer Res, 62, 4690 Bonniaud, 2005, Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor, Am J Respir Crit Care Med, 171, 889, 10.1164/rccm.200405-612OC Konneh, 1998, Tranilast, Kissei Pharmaceuticals, Idrugs, 1, 141 Pfab, 2004, Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug, J Hypertens, 22, 883, 10.1097/00004872-200405000-00006 Koda, 1985, The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid, Int Arch Allergy Appl Immunol, 77, 244, 10.1159/000233800 Shioda, 1979, A double blind controlled trial of N-(3′, 4′-dimethoxycinnamoyl) anthranilic acid on children with bronchial asthma. N-5′ Study Group in Children, Allergy, 34, 213, 10.1111/j.1398-9995.1979.tb01701.x Okuda, 1984, A clinical evaluation of N-5′ with perennial-type allergic rhinitis—a test by the multi-clinic, intergroup, double-blind comparative method, Ann Allergy, 53, 178 Suzawa, 1992, The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts, Jpn J Pharmacol, 60, 91, 10.1016/S0021-5198(19)32429-1 Suzawa, 1992, Effect of tranilast, an anti-allergic drug, on the human keloid tissues, Nippon Yakurigaku Zasshi, 99, 231, 10.1254/fpj.99.231 Yamada, 1994, Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts, J Biochem (Tokyo), 116, 892, 10.1093/oxfordjournals.jbchem.a124612 Mori, 1991, Bleomycin-induced pulmonary fibrosis in genetically mast cell-deficient WBB6F1-W/Wv mice and mechanism of the suppressive effect of tranilast, an antiallergic drug inhibiting mediator release from mast cells, on fibrosis, Int Arch Allergy Appl Immunol, 95, 195, 10.1159/000235429 Isaji, 1994, Inhibition by tranilast of collagen accumulation in hypersensitive granulomatous inflammation in vivo and of morphological changes and functions of fibroblasts in vitro, Life Sci, 55, PL287, 10.1016/0024-3205(94)00668-7 Mori, 1995, Suppressive effects of tranilast on pulmonary fibrosis and activation of alveolar macrophages in mice treated with bleomycin: role of alveolar macrophages in the fibrosis, Jpn J Pharmacol, 67, 279, 10.1254/jjp.67.279 Pinto, 2000, Reduction in left ventricular messenger RNA for transforming growth factor beta(1) attenuates left ventricular fibrosis and improves survival without lowering blood pressure in the hypertensive TGR(mRen2)27 Rat, Hypertension, 36, 747, 10.1161/01.HYP.36.5.747 Hocher, 2002, Inhibition of left ventricular fibrosis by tranilast in rats with renovascular hypertension, J Hypertens, 20, 745, 10.1097/00004872-200204000-00034 Kagitani, 2004, Tranilast attenuates myocardial fibrosis in association with suppression of monocyte/macrophage infiltration in DOCA/salt hypertensive rats, J Hypertens, 22, 1007, 10.1097/00004872-200405000-00024 Jones, 2004, Tranilast reduces mesenteric vascular collagen deposition and chymase-positive mast cells in experimental diabetes, J Diabetes Complicat, 18, 309, 10.1016/j.jdiacomp.2004.02.002 Martin, 2005, Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-beta, Cardiovasc Res, 65, 694, 10.1016/j.cardiores.2004.10.041 Xu, 2007, In vitro models of TGF-beta-induced fibrosis suitable for high-throughput screening of anti-fibrotic agents, Am J Physiol Renal Physiol, 293, F631, 10.1152/ajprenal.00379.2006 Miyazawa, 1995, Inhibition of PDGF- and TGF-beta 1-induced collagen synthesis, migration and proliferation by tranilast in vascular smooth muscle cells from spontaneously hypertensive rats, Atherosclerosis, 118, 213, 10.1016/0021-9150(95)05607-6 Ikeda, 1996, Inhibitory effect of tranilast on activation and transforming growth factor beta 1 expression in cultured rat stellate cells, Biochem Biophys Res Commun, 227, 322, 10.1006/bbrc.1996.1508 Ward, 1998, Inhibitory effects of tranilast on expression of transforming growth factor-beta isoforms and receptors in injured arteries, Atherosclerosis, 137, 267, 10.1016/S0021-9150(97)00275-X Ward, 2002, Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting, Arterioscler Thromb Vasc Biol, 22, 940, 10.1161/01.ATV.0000019405.84384.9C Platten, 2001, N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells, Int J Cancer, 193, 53, 10.1002/ijc.1289 Capper, 2000, Modulation of human monocyte activities by tranilast, SB 252218, a compound demonstrating efficacy in restenosis, J Pharmacol Exp Ther, 295, 1061 Bonnet, 2003, Tranilast attenuates vascular hypertrophy, matrix accumulation and growth factor overexpression in experimental diabetes, Diabetes Metab, 29, 386, 10.1016/S1262-3636(07)70049-6 Yashiro, 2003, Tranilast (N-3,4-dimethoxycinamoyl anthranilic acid): a novel inhibitor of invasion-stimulating interaction between gastric cancer cells and orthotopic fibroblasts, Anticancer Res, 23, 3899 Mifsud, 2003, Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy, Nephron Physiol, 95, p83, 10.1159/000074845 Kelly, 2004, Tranilast attenuates structural and functional aspects of renal injury in the remnant kidney model, J Am Soc Nephrol, 15, 2619, 10.1097/01.ASN.0000139066.77892.04 Akahori, 2005, Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression, J Pharmacol Exp Ther, 314, 514, 10.1124/jpet.105.084772 Qi, 2006, Tranilast attenuates connective tissue growth factor-induced extracellular matrix accumulation in renal cells, Kidney Int, 69, 989, 10.1038/sj.ki.5000189 Kelly, 2006, Combination therapy with tranilast and angiotensin-converting enzyme inhibition provides additional renoprotection in the remnant kidney model, Kidney Int, 69, 1954, 10.1038/sj.ki.5000376 Platten, 2005, Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite, Science, 310, 850, 10.1126/science.1117634 Chikaraishi, 2001, Tranilast inhibits interleukin-1beta-induced monocyte chemoattractant protein-1 expression in rat mesangial cells, Eur J Pharmacol, 427, 151, 10.1016/S0014-2999(01)01215-8 Isaji, 1998, Inhibition by tranilast of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF)-induced increase in vascular permeability in rats, Life Sci, 63, PL71, 10.1016/S0024-3205(98)00277-X Oshitani, 2007, Long-term prospective pilot study with tranilast for the prevention of stricture progression in patients with Crohn's disease, Gut, 56, 599, 10.1136/gut.2006.115469 Nakajima, 2004, Sensitivity of scirrhous gastric cancer to 5-fluorouracil and the role of cancer cell-stromal fibroblast interaction, Oncol Rep, 12, 85 Shime, 2002, Tranilast inhibits the proliferation of uterine leiomyoma cells in vitro through G1 arrest associated with the induction of p21(waf1) and p53, J Clin Endocrinol Metab, 87, 5610, 10.1210/jc.2002-020444 Sata, 2002, Mouse genetic evidence that tranilast reduces smooth muscle cell hyperplasia via a p21(WAF1)-dependent pathway, Arterioscler Thromb Vasc Biol, 22, 1305, 10.1161/01.ATV.0000026614.72957.E7 Wolf, 2006, Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway, Kidney Int, 70, 1914, 10.1038/sj.ki.5001846 Bujak, 2007, The role of TGF-beta signaling in myocardial infarction and cardiac remodeling, Cardiovasc Res, 74, 184, 10.1016/j.cardiores.2006.10.002 Tox, 2006, Impact of inhibitors of the renin–angiotensin–aldosterone system on liver fibrosis and portal hypertension, Curr Med Chem, 13, 3649, 10.2174/092986706779026138 Yao, 2006, Losartan attenuates bleomycin-induced pulmonary fibrosis in rats, Respiration, 73, 236, 10.1159/000090140 Cohn, 2007, Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states, Nat Med, 13, 204, 10.1038/nm1536 Zhou, 2006, Thrombospondin 1 mediates angiotensin II induction of TGF-beta activation by cardiac and renal cells under both high and low glucose conditions, Biochem Biophys Res Commun, 339, 633, 10.1016/j.bbrc.2005.11.060 Dussaule, 2007, Reversal of renal disease: is it enough to inhibit the action of angiotensin II?, Cell Death Differ, 14, 1343, 10.1038/sj.cdd.4402143 Redondo, 2007, TGF-beta1: a novel target for cardiovascular pharmacology, Cytokine Growth Factor Rev, 18, 279, 10.1016/j.cytogfr.2007.04.005 Kim, 2000, Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression, Kidney Int Suppl, 77, S88, 10.1046/j.1523-1755.2000.07714.x Watts, 2004, Connective tissue growth factor expression and induction by transforming growth factor-beta is abrogated by simvastatin via a Rho signaling mechanism, Am J Physiol Lung Cell Mol Physiol, 287, L1323, 10.1152/ajplung.00447.2003 Vieira, 2005, Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis in rats with unilateral ureteral obstruction, Nephrol Dial Transplant, 20, 1582, 10.1093/ndt/gfh859 Antoniu, 2006, Pirfenidone for the treatment of idiopathic pulmonary fibrosis, Expert Opin Investig Drugs, 15, 823, 10.1517/13543784.15.7.823 Lasky, 2004, Pirfenidone, IDrugs, 7, 166 Frazier, 2007, Inhibition of ALK5 signaling induces physeal dysplasia in rats, Toxicol Pathol, 35, 284, 10.1080/01926230701198469 Hiroi, 2002, Antitumor effect of N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) on experimental pancreatic cancer, J Nippon Med Sch, 69, 224, 10.1272/jnms.69.224 Murahashi, 1998, Tranilast and cisplatin as an experimental combination therapy for scirrhous gastric cancer, Int J Oncol, 13, 1235 Noguchi, 2003, Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma, Oral Oncol, 39, 240, 10.1016/S1368-8375(02)00092-1 Yatsunami, 2000, Antiangiogenic and antitumor effects of tranilast on mouse lung carcinoma cells, Int J Oncol, 17, 1151 Mehta, 2007, The TGFbeta superfamily in cardiovascular biology, Cardiovasc Res, 74, 181, 10.1016/j.cardiores.2007.03.011 Piccirillo, 2003, Immune modulation by plasmid DNA-mediated cytokine gene transfer, Curr Pharm Des, 9, 83, 10.2174/1381612033392404 Prud'homme, 2006, Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases, Curr Gene Ther, 6, 243, 10.2174/156652306776359504 Terrell, 1993, Pathology of recombinant human transforming growth factor-beta 1 in rats and rabbits, Int Rev Exp Pathol, 34, 43, 10.1016/B978-0-12-364935-5.50009-2 Lee, 2004, Electroporatic delivery of TGF-beta1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice, J Invest Dermatol, 123, 791, 10.1111/j.0022-202X.2004.23309.x Hirshberg, 2001, TGF-beta3 in the treatment of pressure ulcers: a preliminary report, Adv Skin Wound Care, 14, 91, 10.1097/00129334-200103000-00013 Hermonat, 2007, Mechanism of action and delivery possibilities for TGFbeta1 in the treatment of myocardial ischemia, Cardiovasc Res, 74, 235, 10.1016/j.cardiores.2007.01.016 Grainger, 2007, TGF-beta and atherosclerosis in man, Cardiovasc Res, 74, 213, 10.1016/j.cardiores.2007.02.022 Glinka, 2006, Protective regulatory T cell generation in autoimmune diabetes by DNA covaccination with islet antigens and a selective CTLA-4 ligand, Mol Ther, 14, 578, 10.1016/j.ymthe.2006.03.021 Prud'homme, 2007, Plasmid-based gene therapy of diabetes mellitus, Gene Ther, 14, 553, 10.1038/sj.gt.3302907 You, 2006, Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes, Immunol Rev, 212, 185, 10.1111/j.0105-2896.2006.00410.x